Geographic Atrophy Market 2030 | Geographic Atrophy Market Report 2030 | DelveInsight

November 03 02:04 2021
Geographic Atrophy Market 2030 | Geographic Atrophy Market Report 2030 | DelveInsight

DelveInsight has introduced a new market device report of Geographic Atrophy Market

 

Geographic Atrophy Overview

Geographic atrophy (GA) is a chronic progressive degeneration of the macula, as part of late-stage age-related macular degeneration (AMD). The disease is characterized by localized sharply demarcated atrophy of outer retinal tissue, retinal pigment epithelium, and choriocapillaris. It starts typically in the perifoveal region and expands to involve the fovea with time, leading to central scotomas and permanent loss of visual acuity. It is bilateral in most cases.

 

DelveInsight’s “Geographic Atrophy (GA) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Geographic Atrophy (GA) , historical and forecasted epidemiology as well as the Geographic Atrophy (GA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Request for sample- Geographic Atrophy Market Report

 

Some of the key highlights of the Geographic Atrophy market report

  • Globally, more than 5 million people are affected by GA. Also, as per the published study by GER group, the global prevalence of GA is 0.66% in all ages, but it occurs in 0.34% for 65–74 years old, 1.3% for 75–84, and 4.4% over 85 years old.
  • Over 8 million people are affected worldwide with GA, approximately 20% of all individuals with AMD.
  • The overall prevalence rate of geographic atrophy of the US population 40 years and older was 0.81 per 100 people.

 

Geographic Atrophy Market Companies

  1. Hemera Biosciences
  2. Alkeus Pharmaceuticals
  3. Iveric Bio (formerly Ophthotech Corporation)
  4. Apellis Pharmaceuticals

 

Geographic Atrophy Market Insights

Unfortunately, there is no treatment for this condition. However, several pathways have been implicated in the pathogenesis of dry AMD (d-AMD), and many drugs are under evaluation. Trials of novel interventions have been conducted in participants with significant areas of GA already present. It is currently the most pragmatic approach to determine efficacy, as the endpoints are well-validated and approved by the US Food and Drug Administration (US FDA).

 

Geographic Atrophy Diagnosis 

The development of imaging technologies has contributed to the understanding of the genesis and pathophysiological mechanisms of GA secondary to AMD. At present, to distinguish GA from other forms of dry AMD, color fundus photography and biomicroscopy FA examination are used. In addition to this, modern in vivo imaging technology, such as spectral-domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF) allows for non-invasive and rapid quantitative morphological assessment of GA in the clinical setting also being used for GA.

 

Geographic Atrophy Treatment

Currently, there are no approved treatments present for GA. The AREDS study suggested that supplementing the diet of patients with vitamin C, vitamin E, beta-carotene and zinc could significantly reduce the risk of progressing to advanced AMD and sometimes low visual aids and counseling is also helpful. Several therapies which reached in advanced stage of development are already failed, however currently several therapies are in the pipeline to prevent the progression of GA.

 

Geographic Atrophy Market Report Scope

  • The report covers the descriptive overview of Geographic Atrophy (GA) , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Geographic Atrophy (GA) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Geographic Atrophy (GA) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Geographic Atrophy (GA) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Geographic Atrophy (GA) market

 

For More Information- Geographic Atrophy Market Insights

 

 Table of content

1. Key Insights

2. Executive Summary of Geographic Atrophy (GA)

3. KOL Views

4. SWOT Analysis of Geographic Atrophy (GA)

5. Geographic Atrophy: Market Overview at a Glance

6. Geographic Atrophy: Disease Background and Overview

7. Diagnosis/Imaging of GA

8. Epidemiology and Patient Population

9. The United States Epidemiology

10. EU-5 Epidemiology

11. Japan Epidemiology

12. Treatment of GA

13. Unmet Needs

14. Patient Journey of GA

15. Key Endpoints in Geographic Atrophy (GA) Clinical Trials

16. Emerging Therapies

17. Conjoint Analysis of Geographic Atrophy (GA)

18. Geographic Atrophy (GA): Seven Major Market Analysis

19. 7MM Market Size

20. Market Access and Reimbursement of Geographic Atrophy (GA) Therapies

21. Market Drivers of GA

22. Market Barriers of GA

23. Appendix

24. DelveInsight Capabilities

25. Disclaimer

26. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

 

Contact Us

Yash

[email protected]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

view more articles

About Article Author